GLYC250117P5000
- 0.00
- 0.000.00%
GlycoMimetics Newsroom
GlycoMimetics | 10-Q: Q3 2024 Earnings Report
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
Express News | Adage Capital Management LP Reports 7.9% Stake in GlycoMimetics Inc as of Oct 29 - SEC Filing
M&A Deals Roundup: AbbVie, Blackstone, Take-Two Interactive and More
GlycoMimetics Announces Merger With Crescent Biopharma
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
GlycoMimetics GLYC Crescent Merger; Coya COYA Phase 2 Data
Trending Stocks Today | GlycoMimetics Shoots up 227.4%
Top Midday Gainers
GlycoMimetics Shares Are Soaring Tuesday: Here's Why
Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Correction to GlycoMimetics Acquisition Article
GlycoMimetics GLYC Acquisition Deal; Shuttle Pharmaceuticals SHPH Phase 2 Trial Plans
GlycoMimetics Shares Are Trading Higher After the Company Announced It Will Merge With Crescent Biopharma and Secured $200 in Funding to Advance Its Oncology Pipeline.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Express News | Trading Halt: Halt Status Updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
GlycoMimetics Agrees to Be Taken Private by Crescent Biopharma
GlycoMimetics: Combined Co Will Advance Crescent's Portfolio of Precision-Engineered Biologics to Improve Outcomes for Patients With Solid Tumors >GLYC